Several experimental studies in preclinical rodent models of established T2DM have shown that SGLT2 inhibitors could improve vascular endothelial function [18], decrease oxidative stress, ameliorate myocardial fibrosis and enhance cardiac systolic and diastolic functions [19–21]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.